Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: Progress and pitfalls

Proceedings of the Nutrition Society

Volumn 63, Issue 3, 2004, Pages 437-441

  Minnich, Douglas J ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; Critical care; Genetic polymorphism; Sepsis

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; DROTRECOGIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CRITICAL ILLNESS; DISEASE SEVERITY; GENETIC POLYMORPHISM; HUMAN; INJURY; NONHUMAN; PSYCHOLOGICAL ASPECT; SEPSIS; STRESS; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; POLYMORPHISM, GENETIC; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS;

EID: 4344645094     PISSN: 00296651     EISSN: None     Source Type: Journal    
DOI: 10.1079/PNS2004378     Document Type: Conference Paper

References (42)

1. Abraham E (1999) Why immunomodulatory therapies have not worked in sepsis. Intensive Care Medicine 25, 556-566.
2. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R et al. (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351, 929-933.
3. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF et al. (1997) p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. Journal of the American Medical Association 277, 1531-1538.
4. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. Journal of the American Medical Association 273, 934-941.
5. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G & van Hout B (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Critical Care Medicine 31, 1-11.
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J & Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 29, 1303-1310.
7. Baue AE (2000) Multiple organ failure - the discrepancy between our scientific knowledge and understanding and the management of our patients. Langenbecks Archiv für Chirurgie 385, 441-453.
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW & Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 344, 699-709.
9. Bone RC (1996a) Sir Isaac Newton, sepsis, SIRS, and CARS. Critical Care Medicine 24, 1125-1128.
10. Bone RC (1996b) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Critical Care Medicine 24, 163-172.
11. Cecil RL, Goldman L, Bennett JC & Drazen JM (2000) Cecil Textbook of Medicine, vol. 2, pp. 507-511. Philadelphia, PA: W.B. Saunders.
12. Cohen J & Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine 24, 1431-1440.
13. Fang XM, Schroder S, Hoeft A & Stuber F (1999) Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Critical Care Medicine 27, 1330-1334.
14. Feezor RJ & Moldawer LL (2003) Genetic polymorphisms, functional genomics and the host inflammatory response to injury and inflammation. Nestle Nutrition Workshop Series Clinical Performance Programme, pp. 15-32. Farmington, CT: S. Karger Publishing Inc.
15. Fischer E, Marano MA, Barber AE, Hudson A, Lee K, Rock CS et al. (1991) Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. American Journal of Physiology 261, R442-R452.
16. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. Journal of Clinical Investigation 89, 1551-1557.
17. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E & Fisher CJ Jr (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. New England Journal of Medicine 334, 1697-1702.
18. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. (1994a) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Journal of the American Medical Association 271, 1836-1843.
19. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P et al. (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Critical Care Medicine 21, 318-327.
20. Fisher CJ, Opal SM, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC et al. (1994b) Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circulatory Shock 44, 1-8.
21. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA & Fisher CJ Jr (1994c) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Critical Care Medicine 22, 12-21.
22. Fry DE (2000) Sepsis syndrome. American Surgeon 66, 126-132.
23. Glauser MP (2000) Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Critical Care Medicine 28, S4-S8.
24. Grau GE & Maennel DN (1997) TNF inhibition and sepsis - sounding a cautionary note. Nature Medicine 3, 1193-1195.
25. Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB, Murray CK, Peer GT, Emerson TE, Passey RB, Kuo GC, Taylor FB Jr & Emerson TE Jr (1990) Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circulatory Shock 30, 279-292.
26. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, Chang AC, Duerr M, Peer GT et al. (1992) Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. Journal of Trauma 33, 568-573.
27. Huber TS, Gaines GC, Welborn MB, Rosenberg JJ, Seeger JM & Moldawer LL (2000) Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm. Shock 13, 425-434.
28. Ma P, Chen D, Pan J & Du B (2002) Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Critical Care Medicine 30, 1046-1050.
29. Mandell GL, Douglas RG, Bennett JE & Dolin R (2000) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, vol. 2, pp. 806-817. Philadelphia, PA: Churchill Livingstone.
30. Martin GS, Mannino DM, Eaton S & Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine 348, 1546-1554.
31. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F et al. (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. Journal of the American Medical Association 282, 561-568.
32. Oberholzer A, Oberholzer C & Moldawer LL (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16, 83-96.
33. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Critical Care Medicine 25, 1115-1124.
34. Rosenberg JJ, Martin SW, Seely JE, Kinstler O, Gaines GC, Fukuzuka K et al. (2001) Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. Journal of Applied Physiology 91, 2213-2223.
35. Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, Van Aken H, Assmann G & Berendes E (2002) Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Critical Care Medicine 30, 32-37.
36. Tabrizi AR, Zehnbauer BA, Freeman BD & Buchman TG (2001) Genetic markers in sepsis. Journal of the American College of Surgery 192, 106-117.
37. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234, 470-474.
38. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF & Cerami A (1987a) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664.
39. Tracey KJ, Lowry SF, Fahey TJ 3rd, Albert JD, Fong Y, Hesse D et al. (1987b) Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surgery Gynecology and Obstetrics 164, 415-422.
40. Van Zee KJ, Moldawer LL, Oldenburg HS, Thompson WA, Stackpole SA, Montegut WJ et al. (1996) Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. Journal of Immunology 156, 2221-2230.
41. Wheeler AP & Bernard GR (1999) Treating patients with severe sepsis. New England Journal of Medicine 340, 207-214.
42. Zeni F, Freeman B & Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Critical Care Medicine 25, 1095-1100.